Beckman Coulter Life Sciences has entered into an agreement to acquire Xitogen Technologies, Inc., together with Cytojene Corporation. Xitogen, a flow cytometer developer based in Suzhou and Dalian, China, will provide Beckman Coulter Life Sciences with a high-quality research instrument to round out its cytometry offering. The acquisition is expected to close in the second quarter of 2014. The acquisition of the Xitogen business includes fully staffed facilities in Suzhou and Dalian, which will function as research and development and manufacturing centers for Beckman Coulter Life Sciences.
Xitogen has developed the XTG-1600, a small footprint cytometer that can detect objects in the 100 nanometer range—viruses, bacteria, microparticles, and cell organelles. The base single-laser/four-channel system can be incrementally expanded to a three-laser/16-channel configuration.
“We see Xitogen’s technology as an accelerator that will rapidly grow our menu of products and services,” states Jennifer Honeycutt, president of Beckman Coulter Life Sciences. “We believe that Xitogen offers significant synergies within several of our strategic focus areas, which will help to advance our mission of delivering innovative and trusted scientific solutions across the globe.”
Beckman Coulter Life Sciences offers a comprehensive line of cellular analysis products, including the Navios and FC 500 clinical cytometers, the Gallios and CyAn research cytometers, and the MoFlo XDP and Astrios EQ cell sorters. Other products include sample preparation systems, Kaluza software, and a full line of fluorescently-labeled antibodies and associated support products. Learn more about products and services provided by Xitogen Technologies.
Read more
